CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
Completed · Phase 3 · NCT05819775
Conditions: Hereditary Angioedema (HAE)
At a glance
- Research payments reported, 2025
- $104,088
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 22
About the trial
- Sponsor
- CSL Behring
- Tested
- CSL312 (biological)
- Dates
- Started 2023-05-30; completion 2025-11-19
- Results posted
- Yes
The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.
From ClinicalTrials.gov, last updated 2026-06-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $104,088 in research payments for this study in 2025 (70 payments).
Products named: Andembry
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Connie Hsu, MD Allergy & Immunology · Litchfield Park, AZ
- Jonathan A. Bernstein, MD Allergy & Immunology · Cincinnati, OH
- Timothy J. Craig, DO Allergy & Immunology · Hershey, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Penn State State College of Medicine $52,130
- $18,562
- Bernstein Clinical Research Center $18,299
- Research Solutions of Arizona (dcrpi) $15,098
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.